DDInter1538 DDInter927
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. Propofol may be used prior to diagnostic procedures requiring anaesthesia, in the management of refractory status epilepticus, and for induction and/or maintenance of anaesthesia prior to and during surgeries.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Propofol {u} (Compound) resembles {v} (Compound) Fospropofol
Propofol {u} (Compound) treats {v} (Disease) epilepsy syndrome
Propofol {u} (Compound) binds {v} (Gene) CYP2B6
Propofol {u} (Compound) is included by {v} (Pharmacologic Class) General Anesthesia
Propofol {u} (Compound) downregulates {v} (Gene) NPDC1
Propofol {u} (Compound) causes {v} (Side Effect) Bronchospasm
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dyphylline
Propofol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Propofol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Propofol (Compound) resembles Fospropofol (Compound)
Propofol (Compound) treats epilepsy syndrome (Disease)
Propofol (Compound) binds CYP2B6 (Gene)
Propofol (Compound) is included by General Anesthesia (Pharmacologic Class)
Propofol (Compound) downregulates NPDC1 (Gene)
Propofol (Compound) causes Bronchospasm (Side Effect)
Propofol may cause a minor interaction that can limit clinical effects when taken with Dyphylline
Propofol may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Propofol may cause a moderate interaction that could exacerbate diseases when taken with Astemizole